Biogen headquarters on Binney Street on Thursday, March 21, 2019 in Cambridge, Massachusetts.
Nicolaus Czarnecki | MediaNews Group | Getty Images
The landmark approval of Biogen's Alzheimer's therapy drug should be a big winner for the company even if the treatment is used only by a small percentage of patients, according to investment firm Cowen.
The company's stock surged 38% on Monday following the approval of the drug, which goes by the name Aduhelm.
In upgrading the stock to outperform from market perform, Cowen analyst Phil Nadeau said in an investor note that the shares have further upside.
https://ift.tt/3cqwUpD
Business
Bagikan Berita Ini
0 Response to "Cowen upgrades Biogen and doubles price target after Alzheimer's drug approval - CNBC"
Post a Comment